📢 New Article in #LiversMDPI
🧬 In Japanese patients with HCV, interferon-free DAA therapy was associated with early HRQoL improvements.
🩺 Generic utility scores changed little.
📖 Read More: www.mdpi.com/2673-4389/6/...
#HepatitisC #DAAs #HRQoL
🧬 In Japanese patients with HCV, interferon-free DAA therapy was associated with early HRQoL improvements.
🩺 Generic utility scores changed little.
📖 Read More: www.mdpi.com/2673-4389/6/...
#HepatitisC #DAAs #HRQoL
September 28, 2026 at 8:17 AM
📢 New Article in #LiversMDPI
🧬 In Japanese patients with HCV, interferon-free DAA therapy was associated with early HRQoL improvements.
🩺 Generic utility scores changed little.
📖 Read More: www.mdpi.com/2673-4389/6/...
#HepatitisC #DAAs #HRQoL
🧬 In Japanese patients with HCV, interferon-free DAA therapy was associated with early HRQoL improvements.
🩺 Generic utility scores changed little.
📖 Read More: www.mdpi.com/2673-4389/6/...
#HepatitisC #DAAs #HRQoL
📢 New Article in #LiversMDPI
🧬 TJLB was technically successful in 86 of 100 cases.
🩺 A larger HV–IVC confluence angle was associated with technical failure; the 56° cutoff remains exploratory.
📖 Read More: www.mdpi.com/2673-4389/6/...
#LiverBiopsy
🧬 TJLB was technically successful in 86 of 100 cases.
🩺 A larger HV–IVC confluence angle was associated with technical failure; the 56° cutoff remains exploratory.
📖 Read More: www.mdpi.com/2673-4389/6/...
#LiverBiopsy
September 28, 2026 at 8:22 AM
📢 New Article in #LiversMDPI
🧬 TJLB was technically successful in 86 of 100 cases.
🩺 A larger HV–IVC confluence angle was associated with technical failure; the 56° cutoff remains exploratory.
📖 Read More: www.mdpi.com/2673-4389/6/...
#LiverBiopsy
🧬 TJLB was technically successful in 86 of 100 cases.
🩺 A larger HV–IVC confluence angle was associated with technical failure; the 56° cutoff remains exploratory.
📖 Read More: www.mdpi.com/2673-4389/6/...
#LiverBiopsy
📢 New Review in #LiversMDPI
🧬 Kaur et al. review PPAR agonists across PBC and other liver diseases.
🩺 The review covers molecular pharmacology and clinical and preclinical evidence.
📖 Read More: www.mdpi.com/2673-4389/6/...
#PPARAgonist #PBC #MASLD #Fibrosis
🧬 Kaur et al. review PPAR agonists across PBC and other liver diseases.
🩺 The review covers molecular pharmacology and clinical and preclinical evidence.
📖 Read More: www.mdpi.com/2673-4389/6/...
#PPARAgonist #PBC #MASLD #Fibrosis
September 23, 2026 at 10:28 AM
📢 New Review in #LiversMDPI
🧬 Kaur et al. review PPAR agonists across PBC and other liver diseases.
🩺 The review covers molecular pharmacology and clinical and preclinical evidence.
📖 Read More: www.mdpi.com/2673-4389/6/...
#PPARAgonist #PBC #MASLD #Fibrosis
🧬 Kaur et al. review PPAR agonists across PBC and other liver diseases.
🩺 The review covers molecular pharmacology and clinical and preclinical evidence.
📖 Read More: www.mdpi.com/2673-4389/6/...
#PPARAgonist #PBC #MASLD #Fibrosis
📢 New Article in #LiversMDPI
🧬 Cardoso et al. compared oral and IP acetaminophen administration in mouse models of ALF.
🩺 Effective doses: 500 mg/kg oral; 400 mg/kg IP.
📖 Read More: www.mdpi.com/2673-4389/6/...
#Acetaminophen #AcuteLiverFailure #PreclinicalModels
🧬 Cardoso et al. compared oral and IP acetaminophen administration in mouse models of ALF.
🩺 Effective doses: 500 mg/kg oral; 400 mg/kg IP.
📖 Read More: www.mdpi.com/2673-4389/6/...
#Acetaminophen #AcuteLiverFailure #PreclinicalModels
September 23, 2026 at 10:18 AM
📢 New Article in #LiversMDPI
🧬 Cardoso et al. compared oral and IP acetaminophen administration in mouse models of ALF.
🩺 Effective doses: 500 mg/kg oral; 400 mg/kg IP.
📖 Read More: www.mdpi.com/2673-4389/6/...
#Acetaminophen #AcuteLiverFailure #PreclinicalModels
🧬 Cardoso et al. compared oral and IP acetaminophen administration in mouse models of ALF.
🩺 Effective doses: 500 mg/kg oral; 400 mg/kg IP.
📖 Read More: www.mdpi.com/2673-4389/6/...
#Acetaminophen #AcuteLiverFailure #PreclinicalModels
📢 Editor’s Choice in #LiversMDPI
🧪 Pyka et al. developed FibroScan® cap geometries for non-invasive liver assessment using a pig model.
🧬 In vivo results showed high agreement with the numerical model.
📖 More: brnw.ch/21x5qSt
#Elastography #PigLiver #FibroScan
🧪 Pyka et al. developed FibroScan® cap geometries for non-invasive liver assessment using a pig model.
🧬 In vivo results showed high agreement with the numerical model.
📖 More: brnw.ch/21x5qSt
#Elastography #PigLiver #FibroScan
September 23, 2026 at 10:09 AM
📢 Editor’s Choice in #LiversMDPI
🧪 Pyka et al. developed FibroScan® cap geometries for non-invasive liver assessment using a pig model.
🧬 In vivo results showed high agreement with the numerical model.
📖 More: brnw.ch/21x5qSt
#Elastography #PigLiver #FibroScan
🧪 Pyka et al. developed FibroScan® cap geometries for non-invasive liver assessment using a pig model.
🧬 In vivo results showed high agreement with the numerical model.
📖 More: brnw.ch/21x5qSt
#Elastography #PigLiver #FibroScan
📢 Call for Reading in #LiversMDPI
🔬 Villanueva Raisman et al. quantified 108 proteins in 2 µL of plasma.
🧬 Potential biomarkers for stratifying liver fibrosis were identified.
📖 Read More: brnw.ch/21x5oWo
#Fibrosis #Proteomics #MassSpectrometry
🔬 Villanueva Raisman et al. quantified 108 proteins in 2 µL of plasma.
🧬 Potential biomarkers for stratifying liver fibrosis were identified.
📖 Read More: brnw.ch/21x5oWo
#Fibrosis #Proteomics #MassSpectrometry
September 22, 2026 at 10:48 AM
📢 Call for Reading in #LiversMDPI
🔬 Villanueva Raisman et al. quantified 108 proteins in 2 µL of plasma.
🧬 Potential biomarkers for stratifying liver fibrosis were identified.
📖 Read More: brnw.ch/21x5oWo
#Fibrosis #Proteomics #MassSpectrometry
🔬 Villanueva Raisman et al. quantified 108 proteins in 2 µL of plasma.
🧬 Potential biomarkers for stratifying liver fibrosis were identified.
📖 Read More: brnw.ch/21x5oWo
#Fibrosis #Proteomics #MassSpectrometry
📢 One week left for #LiversMdpi Webinar: Biomarkers in #DILI
🎓Event Chair: Prof. Dr. Hartmut Jaeschke
📅16 Sept | 3 pm CEST | 9 am EDT
🔗Free Registration: brnw.ch/21x5uS4
📖 More Information: brnw.ch/21x5uS5
#Hepatitis #OpenAccess
🎓Event Chair: Prof. Dr. Hartmut Jaeschke
📅16 Sept | 3 pm CEST | 9 am EDT
🔗Free Registration: brnw.ch/21x5uS4
📖 More Information: brnw.ch/21x5uS5
#Hepatitis #OpenAccess
September 7, 2026 at 11:12 AM
📢 One week left for #LiversMdpi Webinar: Biomarkers in #DILI
🎓Event Chair: Prof. Dr. Hartmut Jaeschke
📅16 Sept | 3 pm CEST | 9 am EDT
🔗Free Registration: brnw.ch/21x5uS4
📖 More Information: brnw.ch/21x5uS5
#Hepatitis #OpenAccess
🎓Event Chair: Prof. Dr. Hartmut Jaeschke
📅16 Sept | 3 pm CEST | 9 am EDT
🔗Free Registration: brnw.ch/21x5uS4
📖 More Information: brnw.ch/21x5uS5
#Hepatitis #OpenAccess
📢 New Review in #LiversMDPI
🧬 Vignone et al. review PSC-IBD epidemiology, pathophysiology, and management.
🩺 PSC-IBD is linked to increased colorectal cancer and cholangiocarcinoma risks.
📖 Read More: www.mdpi.com/2673-4389/6/...
#PSC #IBD #ColorectalCancer
🧬 Vignone et al. review PSC-IBD epidemiology, pathophysiology, and management.
🩺 PSC-IBD is linked to increased colorectal cancer and cholangiocarcinoma risks.
📖 Read More: www.mdpi.com/2673-4389/6/...
#PSC #IBD #ColorectalCancer
September 22, 2026 at 10:41 AM
📢 New Review in #LiversMDPI
🧬 Vignone et al. review PSC-IBD epidemiology, pathophysiology, and management.
🩺 PSC-IBD is linked to increased colorectal cancer and cholangiocarcinoma risks.
📖 Read More: www.mdpi.com/2673-4389/6/...
#PSC #IBD #ColorectalCancer
🧬 Vignone et al. review PSC-IBD epidemiology, pathophysiology, and management.
🩺 PSC-IBD is linked to increased colorectal cancer and cholangiocarcinoma risks.
📖 Read More: www.mdpi.com/2673-4389/6/...
#PSC #IBD #ColorectalCancer
📢 New Review in #LiversMDPI
🧬 Jones et al. examine HCC complexity and therapeutic challenges, focusing on HuR.
🩺 Preclinical evidence supports HuR inhibition as a potential strategy in HCC.
📖 Read More: www.mdpi.com/2673-4389/6/...
#HCC #HuR #TherapeuticResistance
🧬 Jones et al. examine HCC complexity and therapeutic challenges, focusing on HuR.
🩺 Preclinical evidence supports HuR inhibition as a potential strategy in HCC.
📖 Read More: www.mdpi.com/2673-4389/6/...
#HCC #HuR #TherapeuticResistance
September 22, 2026 at 10:34 AM
📢 New Review in #LiversMDPI
🧬 Jones et al. examine HCC complexity and therapeutic challenges, focusing on HuR.
🩺 Preclinical evidence supports HuR inhibition as a potential strategy in HCC.
📖 Read More: www.mdpi.com/2673-4389/6/...
#HCC #HuR #TherapeuticResistance
🧬 Jones et al. examine HCC complexity and therapeutic challenges, focusing on HuR.
🩺 Preclinical evidence supports HuR inhibition as a potential strategy in HCC.
📖 Read More: www.mdpi.com/2673-4389/6/...
#HCC #HuR #TherapeuticResistance
📢 Call for Reading in #LiversMDPI
🔬 Fennell et al. analyzed 59 chronic MTX users who underwent VCTE.
🧬 MetS was associated with liver injury, independent of cumulative MTX dosage.
📖 More: brnw.ch/21x5mTh
#Methotrexate #MetabolicSyndrome #LiverInjury
🔬 Fennell et al. analyzed 59 chronic MTX users who underwent VCTE.
🧬 MetS was associated with liver injury, independent of cumulative MTX dosage.
📖 More: brnw.ch/21x5mTh
#Methotrexate #MetabolicSyndrome #LiverInjury
September 21, 2026 at 12:29 PM
📢 Call for Reading in #LiversMDPI
🔬 Fennell et al. analyzed 59 chronic MTX users who underwent VCTE.
🧬 MetS was associated with liver injury, independent of cumulative MTX dosage.
📖 More: brnw.ch/21x5mTh
#Methotrexate #MetabolicSyndrome #LiverInjury
🔬 Fennell et al. analyzed 59 chronic MTX users who underwent VCTE.
🧬 MetS was associated with liver injury, independent of cumulative MTX dosage.
📖 More: brnw.ch/21x5mTh
#Methotrexate #MetabolicSyndrome #LiverInjury
📢 New Review in #LiversMDPI
🧬 Yuquimpo et al. describe hCLS macrophage subtypes in steatotic liver disease.
🩺 Most hCLS cells are variations of lipid-associated macrophages.
📖 Read More: www.mdpi.com/2673-4389/6/...
#hCLS #Macrophages #KupfferCells
🧬 Yuquimpo et al. describe hCLS macrophage subtypes in steatotic liver disease.
🩺 Most hCLS cells are variations of lipid-associated macrophages.
📖 Read More: www.mdpi.com/2673-4389/6/...
#hCLS #Macrophages #KupfferCells
September 21, 2026 at 12:33 PM
📢 New Review in #LiversMDPI
🧬 Yuquimpo et al. describe hCLS macrophage subtypes in steatotic liver disease.
🩺 Most hCLS cells are variations of lipid-associated macrophages.
📖 Read More: www.mdpi.com/2673-4389/6/...
#hCLS #Macrophages #KupfferCells
🧬 Yuquimpo et al. describe hCLS macrophage subtypes in steatotic liver disease.
🩺 Most hCLS cells are variations of lipid-associated macrophages.
📖 Read More: www.mdpi.com/2673-4389/6/...
#hCLS #Macrophages #KupfferCells
📢 New Article in #LiversMDPI
🧬 Galla et al. tested a nutraceutical in a gut–pancreas–liver model.
🩺 It reduced lipid accumulation and increased bile acid production.
📖 Read More: www.mdpi.com/2673-4389/6/...
#MASLD #Nutraceuticals #Probiotics
🧬 Galla et al. tested a nutraceutical in a gut–pancreas–liver model.
🩺 It reduced lipid accumulation and increased bile acid production.
📖 Read More: www.mdpi.com/2673-4389/6/...
#MASLD #Nutraceuticals #Probiotics
September 21, 2026 at 12:41 PM
📢 New Article in #LiversMDPI
🧬 Galla et al. tested a nutraceutical in a gut–pancreas–liver model.
🩺 It reduced lipid accumulation and increased bile acid production.
📖 Read More: www.mdpi.com/2673-4389/6/...
#MASLD #Nutraceuticals #Probiotics
🧬 Galla et al. tested a nutraceutical in a gut–pancreas–liver model.
🩺 It reduced lipid accumulation and increased bile acid production.
📖 Read More: www.mdpi.com/2673-4389/6/...
#MASLD #Nutraceuticals #Probiotics
📢 Call for Reading in #LiversMDPI
🧬 Fortier et al. describe a secondary perfusion model for livers declined after normothermic machine perfusion
🩺 Marginal donor case confirms predicted dysfunction
📖 More: brnw.ch/21x5jpM
#OrganDiscard #LiverTransplantation
🧬 Fortier et al. describe a secondary perfusion model for livers declined after normothermic machine perfusion
🩺 Marginal donor case confirms predicted dysfunction
📖 More: brnw.ch/21x5jpM
#OrganDiscard #LiverTransplantation
September 14, 2026 at 11:55 AM
📢 Call for Reading in #LiversMDPI
🧬 Fortier et al. describe a secondary perfusion model for livers declined after normothermic machine perfusion
🩺 Marginal donor case confirms predicted dysfunction
📖 More: brnw.ch/21x5jpM
#OrganDiscard #LiverTransplantation
🧬 Fortier et al. describe a secondary perfusion model for livers declined after normothermic machine perfusion
🩺 Marginal donor case confirms predicted dysfunction
📖 More: brnw.ch/21x5jpM
#OrganDiscard #LiverTransplantation
📢 Editor's Choice Review in #LiversMDPI
🧬 Gut dysbiosis disrupts the gut–liver axis, triggering liver inflammation in MASLD
🩺 Microbiome signatures offer promise as non-invasive biomarkers
📖 Learn more: www.mdpi.com/2673-4389/5/...
#MASLD #GutMicrobiota
🧬 Gut dysbiosis disrupts the gut–liver axis, triggering liver inflammation in MASLD
🩺 Microbiome signatures offer promise as non-invasive biomarkers
📖 Learn more: www.mdpi.com/2673-4389/5/...
#MASLD #GutMicrobiota
August 14, 2026 at 8:09 AM
📢 Editor's Choice Review in #LiversMDPI
🧬 Gut dysbiosis disrupts the gut–liver axis, triggering liver inflammation in MASLD
🩺 Microbiome signatures offer promise as non-invasive biomarkers
📖 Learn more: www.mdpi.com/2673-4389/5/...
#MASLD #GutMicrobiota
🧬 Gut dysbiosis disrupts the gut–liver axis, triggering liver inflammation in MASLD
🩺 Microbiome signatures offer promise as non-invasive biomarkers
📖 Learn more: www.mdpi.com/2673-4389/5/...
#MASLD #GutMicrobiota
📢 Editor's Choice Article in #LiversMDPI
🧬 Homemade R2* test objects calibrate LIC accurately.
🩺 This MRI approach avoids biopsy sampling limits & outperforms existing tools.
📖 Learn More: www.mdpi.com/2673-4389/6/...
#LiverIron #MRI #QuantitativeMRI
🧬 Homemade R2* test objects calibrate LIC accurately.
🩺 This MRI approach avoids biopsy sampling limits & outperforms existing tools.
📖 Learn More: www.mdpi.com/2673-4389/6/...
#LiverIron #MRI #QuantitativeMRI
July 28, 2026 at 6:47 AM
📢 Editor's Choice Article in #LiversMDPI
🧬 Homemade R2* test objects calibrate LIC accurately.
🩺 This MRI approach avoids biopsy sampling limits & outperforms existing tools.
📖 Learn More: www.mdpi.com/2673-4389/6/...
#LiverIron #MRI #QuantitativeMRI
🧬 Homemade R2* test objects calibrate LIC accurately.
🩺 This MRI approach avoids biopsy sampling limits & outperforms existing tools.
📖 Learn More: www.mdpi.com/2673-4389/6/...
#LiverIron #MRI #QuantitativeMRI
📢 Join the ECEB in #LiversMDPI
🌍 Recruiting early-career researchers for the Early Career Editorial Board
🤝 Strengthen influence, boost global exchanges & enrich the editorial board
📖 brnw.ch/21x48Mr
#Hepatology #LiverDiseases #AcademicRecruitment #EarlyCareerResearcher
🌍 Recruiting early-career researchers for the Early Career Editorial Board
🤝 Strengthen influence, boost global exchanges & enrich the editorial board
📖 brnw.ch/21x48Mr
#Hepatology #LiverDiseases #AcademicRecruitment #EarlyCareerResearcher
July 15, 2026 at 7:48 AM
📢 Join the ECEB in #LiversMDPI
🌍 Recruiting early-career researchers for the Early Career Editorial Board
🤝 Strengthen influence, boost global exchanges & enrich the editorial board
📖 brnw.ch/21x48Mr
#Hepatology #LiverDiseases #AcademicRecruitment #EarlyCareerResearcher
🌍 Recruiting early-career researchers for the Early Career Editorial Board
🤝 Strengthen influence, boost global exchanges & enrich the editorial board
📖 brnw.ch/21x48Mr
#Hepatology #LiverDiseases #AcademicRecruitment #EarlyCareerResearcher
📢 Article in #LiversMDPI
🧬 MI-ML differentiated metastatic liver tumors from parasitic cysts via CT radiomics (AUC: 0.9717).
🩺 SHAP highlighted texture entropy and gray level non-uniformity as key features.
📖 Learn More: www.mdpi.com/2673-4389/6/...
#Radiomics #CTImaging #MachineLearning
🧬 MI-ML differentiated metastatic liver tumors from parasitic cysts via CT radiomics (AUC: 0.9717).
🩺 SHAP highlighted texture entropy and gray level non-uniformity as key features.
📖 Learn More: www.mdpi.com/2673-4389/6/...
#Radiomics #CTImaging #MachineLearning
August 4, 2026 at 5:43 AM
📢 Article in #LiversMDPI
🧬 MI-ML differentiated metastatic liver tumors from parasitic cysts via CT radiomics (AUC: 0.9717).
🩺 SHAP highlighted texture entropy and gray level non-uniformity as key features.
📖 Learn More: www.mdpi.com/2673-4389/6/...
#Radiomics #CTImaging #MachineLearning
🧬 MI-ML differentiated metastatic liver tumors from parasitic cysts via CT radiomics (AUC: 0.9717).
🩺 SHAP highlighted texture entropy and gray level non-uniformity as key features.
📖 Learn More: www.mdpi.com/2673-4389/6/...
#Radiomics #CTImaging #MachineLearning
📢 Article in #LiversMDPI
🧬 >4 mets, RAS mutation, T3/T4 stage, & >1000 mL blood loss predict CRLMs recurrence
🩺 Salvage surgery showed similar 5-year OS in small cohorts
📖 Learn More: www.mdpi.com/2673-4389/6/...
#CRLM #Recurrence #SalvageSurgery
🧬 >4 mets, RAS mutation, T3/T4 stage, & >1000 mL blood loss predict CRLMs recurrence
🩺 Salvage surgery showed similar 5-year OS in small cohorts
📖 Learn More: www.mdpi.com/2673-4389/6/...
#CRLM #Recurrence #SalvageSurgery
July 30, 2026 at 8:01 AM
📢 Article in #LiversMDPI
🧬 >4 mets, RAS mutation, T3/T4 stage, & >1000 mL blood loss predict CRLMs recurrence
🩺 Salvage surgery showed similar 5-year OS in small cohorts
📖 Learn More: www.mdpi.com/2673-4389/6/...
#CRLM #Recurrence #SalvageSurgery
🧬 >4 mets, RAS mutation, T3/T4 stage, & >1000 mL blood loss predict CRLMs recurrence
🩺 Salvage surgery showed similar 5-year OS in small cohorts
📖 Learn More: www.mdpi.com/2673-4389/6/...
#CRLM #Recurrence #SalvageSurgery
📢 Review in #LiversMDPI
🧬 #MASLD affects 38% globally; #CHB impacts ~296 million people worldwide
🩺 MASLD may protect against high viral loads, but coexistence may lead to advanced #fibrosis & elevated #HCC risk
📖 www.mdpi.com/2673-4389/6/...
#ChronicHepatitisB #LiverFibrosis
🧬 #MASLD affects 38% globally; #CHB impacts ~296 million people worldwide
🩺 MASLD may protect against high viral loads, but coexistence may lead to advanced #fibrosis & elevated #HCC risk
📖 www.mdpi.com/2673-4389/6/...
#ChronicHepatitisB #LiverFibrosis
July 3, 2026 at 11:37 AM
📢 Review in #LiversMDPI
🧬 #MASLD affects 38% globally; #CHB impacts ~296 million people worldwide
🩺 MASLD may protect against high viral loads, but coexistence may lead to advanced #fibrosis & elevated #HCC risk
📖 www.mdpi.com/2673-4389/6/...
#ChronicHepatitisB #LiverFibrosis
🧬 #MASLD affects 38% globally; #CHB impacts ~296 million people worldwide
🩺 MASLD may protect against high viral loads, but coexistence may lead to advanced #fibrosis & elevated #HCC risk
📖 www.mdpi.com/2673-4389/6/...
#ChronicHepatitisB #LiverFibrosis
📢 One day left for the MDPI World Hepatitis Day Webinar 2026
🕰️ 28 July 2026
📖 Session 1: brnw.ch/21x4s9k - 11:00 am CEST
Registration: brnw.ch/21x4s9i
📖Session 2: brnw.ch/21x4s9h - 02:00 pm CEST
Registration: brnw.ch/21x4s9j
#Hepatitis #WorldHepatitisDay #LiverDiseases #LiversMDPI #MDPIOpenAccess
🕰️ 28 July 2026
📖 Session 1: brnw.ch/21x4s9k - 11:00 am CEST
Registration: brnw.ch/21x4s9i
📖Session 2: brnw.ch/21x4s9h - 02:00 pm CEST
Registration: brnw.ch/21x4s9j
#Hepatitis #WorldHepatitisDay #LiverDiseases #LiversMDPI #MDPIOpenAccess
July 27, 2026 at 8:21 AM
📢 One day left for the MDPI World Hepatitis Day Webinar 2026
🕰️ 28 July 2026
📖 Session 1: brnw.ch/21x4s9k - 11:00 am CEST
Registration: brnw.ch/21x4s9i
📖Session 2: brnw.ch/21x4s9h - 02:00 pm CEST
Registration: brnw.ch/21x4s9j
#Hepatitis #WorldHepatitisDay #LiverDiseases #LiversMDPI #MDPIOpenAccess
🕰️ 28 July 2026
📖 Session 1: brnw.ch/21x4s9k - 11:00 am CEST
Registration: brnw.ch/21x4s9i
📖Session 2: brnw.ch/21x4s9h - 02:00 pm CEST
Registration: brnw.ch/21x4s9j
#Hepatitis #WorldHepatitisDay #LiverDiseases #LiversMDPI #MDPIOpenAccess
📢 Commentary in #LiversMDPI
🧬 55.8% of 86 #WD pts had #autoimmune phenomena (AP), mainly low-titer ANAs/IgG
🩺 #AP-WD pts had worse #hepatic dysfunction, intense inflammation, and ∼4× higher hazard of liver adverse events over 60 mos
📖 www.mdpi.com/2673-4389/6/...
#Wilson’sDisease #LiverCirrhosis
🧬 55.8% of 86 #WD pts had #autoimmune phenomena (AP), mainly low-titer ANAs/IgG
🩺 #AP-WD pts had worse #hepatic dysfunction, intense inflammation, and ∼4× higher hazard of liver adverse events over 60 mos
📖 www.mdpi.com/2673-4389/6/...
#Wilson’sDisease #LiverCirrhosis
July 29, 2026 at 12:06 PM
📢 Commentary in #LiversMDPI
🧬 55.8% of 86 #WD pts had #autoimmune phenomena (AP), mainly low-titer ANAs/IgG
🩺 #AP-WD pts had worse #hepatic dysfunction, intense inflammation, and ∼4× higher hazard of liver adverse events over 60 mos
📖 www.mdpi.com/2673-4389/6/...
#Wilson’sDisease #LiverCirrhosis
🧬 55.8% of 86 #WD pts had #autoimmune phenomena (AP), mainly low-titer ANAs/IgG
🩺 #AP-WD pts had worse #hepatic dysfunction, intense inflammation, and ∼4× higher hazard of liver adverse events over 60 mos
📖 www.mdpi.com/2673-4389/6/...
#Wilson’sDisease #LiverCirrhosis
📢 Join the Early Career Editorial Board of #LiversMdpi
🎓 Livers is recruiting early-career researchers worldwide to join its ECEB and contribute their academic insights and professional expertise.
🔗 More Information: brnw.ch/21x48Mr
#Hepatology #AcademicRecruitment #EarlyCareerResearcher
🎓 Livers is recruiting early-career researchers worldwide to join its ECEB and contribute their academic insights and professional expertise.
🔗 More Information: brnw.ch/21x48Mr
#Hepatology #AcademicRecruitment #EarlyCareerResearcher
September 18, 2026 at 10:08 AM
📢 Join the Early Career Editorial Board of #LiversMdpi
🎓 Livers is recruiting early-career researchers worldwide to join its ECEB and contribute their academic insights and professional expertise.
🔗 More Information: brnw.ch/21x48Mr
#Hepatology #AcademicRecruitment #EarlyCareerResearcher
🎓 Livers is recruiting early-career researchers worldwide to join its ECEB and contribute their academic insights and professional expertise.
🔗 More Information: brnw.ch/21x48Mr
#Hepatology #AcademicRecruitment #EarlyCareerResearcher
📢 Livers #Exceptional #Reviewers List 2026
🎉 Congratulations to our Q2 outstanding reviewer, Dr. Deborah Jean Verran of Ramsay Healthcare, Sydney, Australia!
📖 More details: www.mdpi.com/journal/live...
#Livers #PeerReview #ExceptionalReviewers #LiversMDPI
🎉 Congratulations to our Q2 outstanding reviewer, Dr. Deborah Jean Verran of Ramsay Healthcare, Sydney, Australia!
📖 More details: www.mdpi.com/journal/live...
#Livers #PeerReview #ExceptionalReviewers #LiversMDPI
September 17, 2026 at 11:56 AM
📢 Livers #Exceptional #Reviewers List 2026
🎉 Congratulations to our Q2 outstanding reviewer, Dr. Deborah Jean Verran of Ramsay Healthcare, Sydney, Australia!
📖 More details: www.mdpi.com/journal/live...
#Livers #PeerReview #ExceptionalReviewers #LiversMDPI
🎉 Congratulations to our Q2 outstanding reviewer, Dr. Deborah Jean Verran of Ramsay Healthcare, Sydney, Australia!
📖 More details: www.mdpi.com/journal/live...
#Livers #PeerReview #ExceptionalReviewers #LiversMDPI
📢 Editor’s Choice in #LiversMDPI
🧬 Pedersen et al. used untargeted proteomics on paired visceral adipose and liver biopsies in obesity, #MASLD and #MASH
🩺 Proteomes in both tissues were affected more by #obesity than MASLD severity
📖 More: brnw.ch/21x5kUD
#VisceralAdiposeTissue #LiverTissue
🧬 Pedersen et al. used untargeted proteomics on paired visceral adipose and liver biopsies in obesity, #MASLD and #MASH
🩺 Proteomes in both tissues were affected more by #obesity than MASLD severity
📖 More: brnw.ch/21x5kUD
#VisceralAdiposeTissue #LiverTissue
September 16, 2026 at 7:35 AM
📢 Editor’s Choice in #LiversMDPI
🧬 Pedersen et al. used untargeted proteomics on paired visceral adipose and liver biopsies in obesity, #MASLD and #MASH
🩺 Proteomes in both tissues were affected more by #obesity than MASLD severity
📖 More: brnw.ch/21x5kUD
#VisceralAdiposeTissue #LiverTissue
🧬 Pedersen et al. used untargeted proteomics on paired visceral adipose and liver biopsies in obesity, #MASLD and #MASH
🩺 Proteomes in both tissues were affected more by #obesity than MASLD severity
📖 More: brnw.ch/21x5kUD
#VisceralAdiposeTissue #LiverTissue
📢 New Issue in #LiversMDPI
📚 Volume 6, Issue 4 is now online with 27 articles
⭐ Cover Story: Hepatic crown-like structures, cell heterogeneity, and their role in steatotic liver diseases
🔗 Full issue here: mdpi.com/2673-4389/6/4
#Hepatology #LiverResearch #SteatoticLiver
📚 Volume 6, Issue 4 is now online with 27 articles
⭐ Cover Story: Hepatic crown-like structures, cell heterogeneity, and their role in steatotic liver diseases
🔗 Full issue here: mdpi.com/2673-4389/6/4
#Hepatology #LiverResearch #SteatoticLiver
September 16, 2026 at 7:55 AM
📢 New Issue in #LiversMDPI
📚 Volume 6, Issue 4 is now online with 27 articles
⭐ Cover Story: Hepatic crown-like structures, cell heterogeneity, and their role in steatotic liver diseases
🔗 Full issue here: mdpi.com/2673-4389/6/4
#Hepatology #LiverResearch #SteatoticLiver
📚 Volume 6, Issue 4 is now online with 27 articles
⭐ Cover Story: Hepatic crown-like structures, cell heterogeneity, and their role in steatotic liver diseases
🔗 Full issue here: mdpi.com/2673-4389/6/4
#Hepatology #LiverResearch #SteatoticLiver